Cuprina Holdings (Cayman) Limited — Form 6-K summary
Reporting context: Form 6-K for October 2026, filed October 2, 2026. The filing announces conditional agreements to acquire two Singapore clinic businesses. It does not report financial results for the period.
Transaction overview
On October 1, 2026, wholly owned subsidiary Cuprina Holdings (BVI) Limited agreed to acquire all shares of East Coast Podiatry Centre Pte. Ltd. (Target A), which operates East Coast Podiatry Clinic, and Orchard Clinic Management Pte. Ltd. (Target B), which operates Orchard Clinic, a women’s health and wellness clinic. The clinics will become wholly owned subsidiaries upon completion.
Consideration and key figures
- Total consideration: approximately S$4.0 million, comprising approximately S$0.6 million payable upon signing, S$1.35 million payable at completion, S$1.0 million in company shares, and S$1.15 million in deferred cash payments.
- Share issuance: 301,671 Class A ordinary shares in total; approximately 3.79% of enlarged issued Class A shares after issuance. The shares are subject to lock-ups.
- Payment timing: SPA I includes S$0.4 million due no later than 14 days after its first anniversary. SPA II includes S$0.75 million due no later than 14 days after its second anniversary.
- Target capital: Target A has stated issued and paid-up capital of S$100,000; Target B, S$300,000.
The filing provides no target revenue, profit, cash flow, margins, debt, liquidity, or valuation amounts, and no clear financial effect on Cuprina. It says the consideration was negotiated at arm’s length, considering the targets’ financial condition, operating performance, prospects, assets and liabilities, and an independent valuation adviser’s assessment.
Completion, outlook, and risks
Completion is conditional on shareholder approval to increase the Company’s authorized share capital at an extraordinary general meeting expected on October 15, 2026. The stated completion window is after October 15 and on or before November 1, 2026. The board approved the transactions on October 1. The filing provides no broader financial guidance or quantified outlook.
Key transaction uncertainties include obtaining shareholder approval and completing the acquisitions within the stated window. The filing refers investors to the SPAs and lock-up agreements filed as Exhibits 10.1–10.4; its transaction description is qualified by those agreements.
Most important facts for investors to verify
- Whether shareholders approve the authorized-share-capital increase and the acquisitions close by November 1, 2026.
- The targets’ financial statements, operating performance, liabilities, and the independent valuation supporting the S$4.0 million consideration.
- Final cash-payment obligations, deferred-payment terms, and the lock-up restrictions on the 301,671 consideration shares.
- The resulting ownership dilution and the Company’s funding and liquidity impact.